Open an account

Sagimet Biosciences

SGMT · NASDAQ

$9.74+$0.88 (+9.93%)TodayMarket closed ·
Prev close $8.86

About SGMT

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 16 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Employees
16
Headquarters
San Mateo, California
Listed
Jul 14, 2023
Sector
Health Care
Industry
Biotechnology
Website
sagimet.com

SGMT key statistics

Market cap
685.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.62M
Volume
2.18M
Open price
$8.88
High today
$10.15
Low today
$8.83
52 Week high
$11.45
52 Week low
$4.50

Sagimet Biosciences (SGMT) at a glance

Sagimet Biosciences (SGMT) last traded at $9.74, with a market cap of 685.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.83 and $10.15. The current price is 10.3% above the day's low and 4.0% below its high.

Volume so far is 2.18M shares, above the average of 1.62M shares a day.

Over the past year Sagimet Biosciences has ranged from $4.50 to $11.45, and now sits 75% of the way up that range.

Sagimet Biosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.26 per share against an estimate of -$0.2511.

The average analyst price target is $28.48, 192.4% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

89%of 9 analyst ratings say Buy
  • Buy88.9%
  • Hold0.0%
  • Sell11.1%
Price target · 14 analystsAvg $28.48
Low
$7.07
Now
$9.74
High
$58.80

SGMT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 24.1% on average.

  1. Q3 FY24: reported -$0.45 per share against an estimate of -$0.4153
  2. Q4 FY24: reported -$0.50 per share against an estimate of -$0.6337
  3. Q1 FY25: reported -$0.56 per share against an estimate of -$0.6792
  4. Q2 FY25: reported -$0.32 per share against an estimate of -$0.5176
  5. Q3 FY25: reported -$0.40 per share against an estimate of -$0.3933
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.4149
  7. Q1 FY26: reported -$0.33 per share against an estimate of -$0.3818
  8. Q2 FY26: reported -$0.26 per share against an estimate of -$0.2511

SGMT news

  • Vandana Singh

    Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

  • UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults

  • Vandana Singh

    Why Is Sagimet Biosciences Stock Trading Higher On Monday?

  • Press releasePRNewswire

    Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

  • Press releasePRNewswire

    Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

  • Press releasePRNewswire

    Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

  • Vandana Singh

    Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Sagimet Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.